

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (canceled).

Claim 2 (withdrawn): The method according to claim 7, wherein the agonist is a corticosteroid or a pharmacodynamic equivalent thereof.

Claim 3 (withdrawn): The method according to claim 2, wherein the corticosteroid is selected from the group consisting of cortisol, cortisone, cortisone acetate, corticosterone, prednisolone, prednisone, prednylidene, methylprednisolone, triamcinolone, betamethasone, dexamethasone, paramethasone, fluorcortolone, deflazacort, cloprednol and fludrocortisone, a pharmacodynamic equivalent thereof or a combination thereof.

Claim 4 (withdrawn): The method according to any one of claims 2, 3 or 7, wherein the addictive disease is selected from the group consisting of opiate dependency, psychostimulant dependency, hallucinogen and entactogen dependency, amphetamine dependency, LSD dependency, MDMA

(Ecstasy) dependency, nicotine addiction, cannabinoid dependency, cocaine addiction, "Crack" addiction, or polytoxicomanic addiction.

Claim 5 (currently amended): A ~~pharmaceutical composition~~ kit for the treatment of an addictive disease comprising:

a. a first receptacle comprising at least one agonist selected from a corticosteroid receptor agonist, or a mineralo-corticosteroid receptor agonist, wherein the corticosteroid receptor agonist or mineralo-corticosteroid receptor agonist is selected from the group consisting of cortisol, cortisone, cortisone acetate, corticosterone, prednisolone, prednisone, prednylidene, methylprednisolone, triamcinolone, betamethasone, dexamethasone, paramethasone, fluorcortolone, deflazacort, cloprednol, fludrocortisone, a pharmacodynamic equivalent thereof, and a combination thereof; and

b. a second receptacle comprising an addictive drug responsible for the addictive disease, wherein the addictive drug is selected from the group consisting of opioid, nicotine, cannabinoid, amphetamine, cocaine,

Crack, MDMA (Ecstasy), or and a pharmacodynamic equivalent thereof; and

b. at least one agonist selected from the group consisting of a corticosteroid receptor agonist, and a mineralo-corticosteroid receptor agonist or, wherein the corticosteroid receptor agonist or mineralo-corticosteroid receptor agonist is selected from the group consisting of cortisol, cortisone, cortisone acetate, corticosterone, prednisolone, prednisone, prednylidene, methylprednisolone, triamcinolone, betamethasone, dexamethasone, paramethasone, fluorcortolone, deflazacort, cloprednol, fludrocortisone, a pharmacodynamic equivalent thereof, and a combination thereof.

Claim 6 (currently amended): The pharmaceutical composition kit according to claim 5 wherein the addictive drug or a pharmacodynamic equivalent thereof is in a high dose and wherein the maintenance dose of at least one corticosteroid agonist is in the amount of 0.5-100 mg/day and 2 to 10 times higher amount for the initial dosage for a patient having a body weight of 60-80 kg.

Claim 7 (withdrawn) : A method of treating an addictive disease caused by an addictive drug or in connection with the addictive drug comprising the step of administering a composition comprising:

- a. at least one agonist selected from the group consisting of a corticosteroid receptor agonist, a mineralo-corticosteroid receptor agonist, or a combination thereof; and
- b. the addictive drug or a pharmacodynamic equivalent thereof.

Claim 8 (withdrawn) : The method according to claim 7, wherein a preparing treatment of at least one corticosteroid receptor agonist is administered prior to the treatment with the combination of agonist and addictive drug.

Claim 9 (withdrawn) : The method according to claim 7, wherein the treatment with the composition of agonist and addictive drug is followed by the administration of an addictive drug or a pharmacodynamic equivalent thereof.

Claim 10 (withdrawn) : The method according to claim 7, wherein the treatment with the composition of agonist and

addictive drug is followed by a forced application of an addictive drug or a pharmacodynamic equivalent thereof.

Claim 11-12 (canceled).

Claim 13 (currently amended): The pharmaceutical composition kit according to claim 5, wherein the addictive drug is an opioid.

Claim 14 (currently amended): The pharmaceutical composition kit according to claim 5, wherein the addictive drug is nicotine.

Claim 15 (currently amended): The pharmaceutical composition kit according to claim 5, wherein the addictive drug is a cannabinoid.

Claim 16 (currently amended): The pharmaceutical composition kit according to claim 5, wherein the addictive drug is an amphetamine.

Claim 17 (currently amended): The pharmaceutical composition kit according to claim 5, wherein the addictive drug is cocaine.

Claim 18 (currently amended): The pharmaceutical composition kit according to claim 5, wherein the addictive drug is Crack.

Claim 19 (currently amended): The pharmaceutical composition kit according to claim 5, wherein the addictive drug is MDMA (Ecstasy).

Claim 20 (currently amended): The pharmaceutical composition kit according to claim 5 ~~12~~, wherein the addictive drug is selected from the group consisting of an opioid and nicotine and the corticosteroid receptor agonist is selected from the group consisting of dexamethasone and corticosterone.

Claim 21 (currently amended): The pharmaceutical composition kit according to claim 20, wherein the addictive drug is an opioid.

Claim 22 (withdrawn): The method according to claim 7 wherein the addictive drug is selected from the group consisting of an opioid, nicotine, cannabinoid, amphetamine, cocaine, Crack, MDMA (Ecstasy), or a pharmacodynamic equivalent thereof; and wherein the corticosteroid receptor agonist is selected from the group consisting of cortisol, cortisone, cortisone

acetate, corticosterone, prednisolone, prednisone, prednylidene, methylprednisolone, triamcinolone, betamethasone, dexamethasone, paramethasone, fluorcortolone, deflazacort, cloprednol and fludrocortisone, a pharmacodynamic equivalent thereof or a combination thereof.

Claim 23 (withdrawn): The method according to claim 22, wherein the addictive drug is selected from the group consisting of an opioid and nicotine and the corticosteroid receptor agonist is selected from dexamethasone and corticosterone.

Claim 24 (withdrawn): The method according to claim 23, wherein the addictive drug is an opioid.

Claim 25 (currently amended): The pharmaceutical composition kit according to claim 5 12, wherein the addictive drug is an opioid and the corticosteroid receptor agonist is prednisolone.

Claim 26 (new): The kit according to claim 13, wherein the opioid is selected from morphine, codeine, dihydrocodeine, levomethadone, and tilidin.